Jonas Bredtoft Boel

Medicine & Life Sciences

1. Amdinocillin Pivoxil 100%
2. Bacteremia 88%
3. Anti-Bacterial Agents 83%
4. Antimicrobial Stewardship 83%
5. Cohort Studies 79%
6. Chronic Obstructive Pulmonary Disease 74%
7. Streptococcal Infections 67%
8. Escherichia coli 60%
9. Denmark 57%
10. Community-Acquired Infections 55%
11. Adrenal Cortex Hormones 50%
12. Endocarditis 43%
13. Urinary Tract Infections 42%
14. Pseudomonas aeruginosa 38%
15. Blood Culture 36%
16. Retrospective Studies 36%
17. Mortality 36%
18. Amdinocillin 34%
19. Fungemia 30%
20. Lactams 29%
21. Interrupted Time Series Analysis 29%
22. Pneumococcal Infections 25%
23. Confidence Intervals 25%
24. Klebsiella 24%
25. Antibiotic Prophylaxis 24%
26. Treatment Failure 24%
27. Haemophilus influenzae 23%
28. Duration of Therapy 23%
29. Epidemiologic Studies 23%
30. beta-Lactamases 22%
31. Gentamicins 21%
32. Mycoses 21%
33. Penicillins 21%
34. Urinary Tract 20%
35. Amoxicillin-Potassium Clavulanate Combination 20%
36. Infections 19%
37. Culture Media 19%
38. Ciprofloxacin 18%
39. Fluoroquinolones 18%
40. Health Personnel 18%
41. Primary Health Care 17%
42. Odds Ratio 17%
43. Echocardiography 17%
44. Prostate 17%
45. Cephalosporins 17%
46. Cefuroxime 17%
47. Hypersensitivity 17%
48. Pregnant Women 16%
49. Observational Studies 16%
50. Prescriptions 16%